Dorzolamide and ocular blood flow in previously untreated glaucoma patients: A controlled double-masked study

Ingar C. Bergstrand, Anders Heijl, Alon Harris

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: The aim of this study was to investigate the haemodynamic effects of topical dorzolamide treatment in eyes with newly detected and previously untreated glaucoma. Methods: Forty-seven patients with open angle glaucoma were consecutively randomized to dorzolamide versus placebo TID during a 6-week double-masked treatment trial. Ocular blood flow was investigated at baseline and on therapy using colour Doppler imaging of the retrobulbar vessels and scanning laser ophthalmoscope fluorescein angiograms of the retinal circulation. Results: None of the flow parameters, retrobulbar or retinal, changed significantly on therapy when the results were analysed with the Bonferroni method. Analysis with non-simultaneous tests also failed to reveal any significant changes either in retrobulbar flow velocities in the central retinal artery, ophthalmic artery or in the short posterior ciliary arteries, or in the retinal parameters (arm-retina time, arteriovenous passage time, mean dye velocity or macular capillary velocity), while capillary velocities at the optic disc decreased significantly in the dorzolamide group (P = 0.03). Intraocular pressure reduction was significantly more pronounced in the dorzolamide group (P = 0.002), with - 4.8 ± 2.9 mmHg (P < 0.0001) versus - 1.8 ± 3.0 mmHg in the placebo group (P = 0.006). Conclusions: The present study indicated no measurable vascular effects from topical dorzolamide treatment in previously untreated glaucoma eyes.

Original languageEnglish
Pages (from-to)176-182
Number of pages7
JournalActa Ophthalmologica Scandinavica
Volume80
Issue number2
DOIs
StatePublished - 2002

Fingerprint

dorzolamide
Double-Blind Method
Glaucoma
Color Therapy
Ciliary Arteries
Placebos
Ophthalmic Artery
Retinal Artery
Ophthalmoscopes
Open Angle Glaucoma
Optic Disk
Therapeutics
Fluorescein
Intraocular Pressure
Blood Vessels
Retina
Angiography
Lasers
Arm
Coloring Agents

Keywords

  • Blood flow
  • Carbonic anhydrase inhibitors
  • Glaucoma
  • Glaucoma medications
  • Ophthalmic artery
  • Optic nerve
  • Retinal artery
  • Sulfonamides
  • Thiophenes

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Dorzolamide and ocular blood flow in previously untreated glaucoma patients : A controlled double-masked study. / Bergstrand, Ingar C.; Heijl, Anders; Harris, Alon.

In: Acta Ophthalmologica Scandinavica, Vol. 80, No. 2, 2002, p. 176-182.

Research output: Contribution to journalArticle

@article{629604f7be0e474892d560b7a49948a2,
title = "Dorzolamide and ocular blood flow in previously untreated glaucoma patients: A controlled double-masked study",
abstract = "Purpose: The aim of this study was to investigate the haemodynamic effects of topical dorzolamide treatment in eyes with newly detected and previously untreated glaucoma. Methods: Forty-seven patients with open angle glaucoma were consecutively randomized to dorzolamide versus placebo TID during a 6-week double-masked treatment trial. Ocular blood flow was investigated at baseline and on therapy using colour Doppler imaging of the retrobulbar vessels and scanning laser ophthalmoscope fluorescein angiograms of the retinal circulation. Results: None of the flow parameters, retrobulbar or retinal, changed significantly on therapy when the results were analysed with the Bonferroni method. Analysis with non-simultaneous tests also failed to reveal any significant changes either in retrobulbar flow velocities in the central retinal artery, ophthalmic artery or in the short posterior ciliary arteries, or in the retinal parameters (arm-retina time, arteriovenous passage time, mean dye velocity or macular capillary velocity), while capillary velocities at the optic disc decreased significantly in the dorzolamide group (P = 0.03). Intraocular pressure reduction was significantly more pronounced in the dorzolamide group (P = 0.002), with - 4.8 ± 2.9 mmHg (P < 0.0001) versus - 1.8 ± 3.0 mmHg in the placebo group (P = 0.006). Conclusions: The present study indicated no measurable vascular effects from topical dorzolamide treatment in previously untreated glaucoma eyes.",
keywords = "Blood flow, Carbonic anhydrase inhibitors, Glaucoma, Glaucoma medications, Ophthalmic artery, Optic nerve, Retinal artery, Sulfonamides, Thiophenes",
author = "Bergstrand, {Ingar C.} and Anders Heijl and Alon Harris",
year = "2002",
doi = "10.1034/j.1600-0420.2002.800211.x",
language = "English",
volume = "80",
pages = "176--182",
journal = "Acta Ophthalmologica",
issn = "1755-375X",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Dorzolamide and ocular blood flow in previously untreated glaucoma patients

T2 - A controlled double-masked study

AU - Bergstrand, Ingar C.

AU - Heijl, Anders

AU - Harris, Alon

PY - 2002

Y1 - 2002

N2 - Purpose: The aim of this study was to investigate the haemodynamic effects of topical dorzolamide treatment in eyes with newly detected and previously untreated glaucoma. Methods: Forty-seven patients with open angle glaucoma were consecutively randomized to dorzolamide versus placebo TID during a 6-week double-masked treatment trial. Ocular blood flow was investigated at baseline and on therapy using colour Doppler imaging of the retrobulbar vessels and scanning laser ophthalmoscope fluorescein angiograms of the retinal circulation. Results: None of the flow parameters, retrobulbar or retinal, changed significantly on therapy when the results were analysed with the Bonferroni method. Analysis with non-simultaneous tests also failed to reveal any significant changes either in retrobulbar flow velocities in the central retinal artery, ophthalmic artery or in the short posterior ciliary arteries, or in the retinal parameters (arm-retina time, arteriovenous passage time, mean dye velocity or macular capillary velocity), while capillary velocities at the optic disc decreased significantly in the dorzolamide group (P = 0.03). Intraocular pressure reduction was significantly more pronounced in the dorzolamide group (P = 0.002), with - 4.8 ± 2.9 mmHg (P < 0.0001) versus - 1.8 ± 3.0 mmHg in the placebo group (P = 0.006). Conclusions: The present study indicated no measurable vascular effects from topical dorzolamide treatment in previously untreated glaucoma eyes.

AB - Purpose: The aim of this study was to investigate the haemodynamic effects of topical dorzolamide treatment in eyes with newly detected and previously untreated glaucoma. Methods: Forty-seven patients with open angle glaucoma were consecutively randomized to dorzolamide versus placebo TID during a 6-week double-masked treatment trial. Ocular blood flow was investigated at baseline and on therapy using colour Doppler imaging of the retrobulbar vessels and scanning laser ophthalmoscope fluorescein angiograms of the retinal circulation. Results: None of the flow parameters, retrobulbar or retinal, changed significantly on therapy when the results were analysed with the Bonferroni method. Analysis with non-simultaneous tests also failed to reveal any significant changes either in retrobulbar flow velocities in the central retinal artery, ophthalmic artery or in the short posterior ciliary arteries, or in the retinal parameters (arm-retina time, arteriovenous passage time, mean dye velocity or macular capillary velocity), while capillary velocities at the optic disc decreased significantly in the dorzolamide group (P = 0.03). Intraocular pressure reduction was significantly more pronounced in the dorzolamide group (P = 0.002), with - 4.8 ± 2.9 mmHg (P < 0.0001) versus - 1.8 ± 3.0 mmHg in the placebo group (P = 0.006). Conclusions: The present study indicated no measurable vascular effects from topical dorzolamide treatment in previously untreated glaucoma eyes.

KW - Blood flow

KW - Carbonic anhydrase inhibitors

KW - Glaucoma

KW - Glaucoma medications

KW - Ophthalmic artery

KW - Optic nerve

KW - Retinal artery

KW - Sulfonamides

KW - Thiophenes

UR - http://www.scopus.com/inward/record.url?scp=0036123663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036123663&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0420.2002.800211.x

DO - 10.1034/j.1600-0420.2002.800211.x

M3 - Article

C2 - 11952485

AN - SCOPUS:0036123663

VL - 80

SP - 176

EP - 182

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

SN - 1755-375X

IS - 2

ER -